GCM
ATYR

Graham Capital Management’s aTyr Pharma ATYR Stock Holding History

Graham Capital Management’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-147,851
Closed -$107K – 1637
2025
Q3 		$107K Buy
+147,851
New +$670K ﹤0.01% 1153

Other funds holding ATYR

RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Graham Capital Management's ATYR Position: Q4 2025 in Review

Graham Capital Management sold out of aTyr Pharma (ATYR) in Q4 2025, closing a stake of 147,851 shares — an estimated $107K sold.

Graham Capital Management first reported a position in ATYR in Q3 2025 and held it in 1 quarter. The position peaked at $107K in Q3 2025. 84 funds tracked by Wall St. Rank hold ATYR as of Q4 2025.

  • Graham Capital Management reported no remaining aTyr Pharma position as of Q4 2025 after selling out during the quarter.
  • Graham Capital Management sold 147,851 aTyr Pharma shares in Q4 2025, an estimated $107K.
  • Graham Capital Management first reported a position in aTyr Pharma in Q3 2025 and held it in 1 quarter.
  • Graham Capital Management's aTyr Pharma position peaked at $107K in Q3 2025.
  • 84 funds tracked by Wall St. Rank held aTyr Pharma as of Q4 2025.

Based on Graham Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.